Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Fort Myers, FL
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Status: Enrolling
Updated:  8/1/2016
mi
from
Ottawa,
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
Status: Enrolling
Updated: 8/1/2016
mi
from
Ottawa,
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Tucson, AZ
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Stanford, CA
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Denver, CO
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Hollywood, FL
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Miami, FL
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Plantation, FL
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Plantation, FL
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Marietta, GA
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Marietta, GA
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Morristown, NJ
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Morristown, NJ
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Durham, NC
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Columbus, OH
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Ogden, UT
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Fredericksburg, VA
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Fredericksburg, VA
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated:  8/1/2016
mi
from
Rio de Janeiro,
A Study of Pertuzumab in Combination With Herceptin (Trastuzumab) And Vinorelbine in First Line in Patients With Metastatic or Locally Advanced HER2-Positive Breast Cancer
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.
Status: Enrolling
Updated: 8/1/2016
mi
from
Rio de Janeiro,
Click here to add this to my saved trials
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy
Status: Enrolling
Updated:  8/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy
Status: Enrolling
Updated: 8/1/2016
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy
Status: Enrolling
Updated:  8/1/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy
Status: Enrolling
Updated: 8/1/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy
Status: Enrolling
Updated:  8/1/2016
Faulkner Hospital
mi
from
Boston, MA
Breast MRI for Newly Diagnosed Breast Cancer:Impact on Re-excision Lumpectomy
Randomized Trail of Breast MRI for Newly Diagnosed Early Stage Breast Cancer: Impact on Re-excision Lumpectomy
Status: Enrolling
Updated: 8/1/2016
Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Boston, MA
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Santa Monica, CA
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Hackensack, NJ
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/1/2016
Research Site
mi
from
Bordeaux,
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
A Multi-center, Open-label Phase IB Study of Escalating Doses of RO5045337, an Oral Small Molecule MDM2 Antagonist, in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/1/2016
Research Site
mi
from
Bordeaux,
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Goodyear, AZ
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Goodyear, AZ
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Salinas, CA
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Salinas, CA
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Whittier, CA
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Whittier, CA
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Englewood, CO
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Englewood, CO
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Farmington, CT
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Farmington, CT
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New Britain, CT
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New Britain, CT
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Augusta, GA
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Hinsdale, IL
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Hinsdale, IL
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Joliet, IL
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Skokie, IL
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Skokie, IL
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Cumberland, MD
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Cumberland, MD
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Missoula, MT
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Missoula, MT
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Lincoln, NE
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Buffalo, NY
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Buffalo, NY
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New York, NY
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Watertown, NY
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Watertown, NY
Click here to add this to my saved trials
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Canton, OH
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
Patient Reported Symptoms in Ovarian Cancer
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Canton, OH
Click here to add this to my saved trials